Wird geladen...
PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB(1) receptors with hypophagic effects in rats
BACKGROUND AND PURPOSE: Rimonabant (Acomplia(TM), SR141716A), a cannabinoid CB(1) receptor inverse agonist, has recently been approved for the treatment of obesity. There are, however, concerns regarding its side effect profile. Developing a CB(1) antagonist with a different pharmacological mechanis...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Nature Publishing Group
2007
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2190018/ https://ncbi.nlm.nih.gov/pubmed/17592509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjp.0707347 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|